On August 25, 2026, the Federal Trade Commission (FTC) announced it had finalized a consent order resolving antitrust concerns arising from Ascension Health Alliance’s $3.9 billion acquisition of AmSurg. This order arrives against the backdrop of heightened FTC attention to the healthcare sector. In March 2026, FTC Chairman Andrew Ferguson directed the agency to form a Healthcare Task Force to pursue a “coordinated, integrated approach” to healthcare enforcement and advocacy in coordination with other agencies and law enforcement partners (such as the Department of Health and Human Services and Department of Justice). The final order in the Ascension/AmSurg matter reflects this continued focus and offers a useful window into how the FTC is applying it in practice.
Key takeaways
- Local market power remains key antitrust risk. The FTC’s challenge focused on competition concerns in five specific metro areas and three outpatient surgery services, underscoring that even relatively small local overlaps can draw scrutiny regardless of overall deal size. Healthcare providers should continue to expect market-by-market and service-by-service antitrust review.
- FTC oversight can extend well beyond Hart-Scott-Rodino (HSR) requirements. Under the settlement, Ascension must provide 30 days’ notice before acquiring any outpatient surgery center in the affected markets for the next 10 years, including transactions below HSR thresholds. This highlights the FTC’s willingness to impose long-term monitoring obligations following healthcare enforcement actions.
- The FTC continues to actively pursue its enforcement agenda and prioritize healthcare enforcement. The Ascension/AmSurg divestitures, coupled with the FTC’s recent federal court victory blocking Henkel’s acquisition of Liquid Nails, demonstrate that the agency is following through on its enforcement priorities, not just announcing them.
